{"id":"ssri-snri","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"20-40","effect":"Sexual dysfunction"},{"rate":"10-20","effect":"Insomnia or somnolence"},{"rate":"5-15","effect":"Dry mouth"},{"rate":"10-15","effect":"Diarrhea or constipation"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL284994","moleculeType":"Small molecule","molecularWeight":"306.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Selective serotonin reuptake inhibitors (SSRIs) block the serotonin transporter, preventing reabsorption of serotonin into presynaptic neurons and increasing its availability at the synapse. Serotonin-norepinephrine reuptake inhibitors (SNRIs) additionally block norepinephrine reuptake, providing dual monoamine enhancement. This increased synaptic concentration of these neurotransmitters is thought to restore normal mood and reduce anxiety and depressive symptoms over weeks of treatment.","oneSentence":"SSRIs and SNRIs increase serotonin (and norepinephrine for SNRIs) in the brain by blocking their reuptake from the synaptic cleft, thereby enhancing mood regulation and emotional processing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:59.855Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Social anxiety disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Post-traumatic stress disorder"}]},"trialDetails":[{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT05841030","phase":"","title":"A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-28","conditions":"Depressive Disorder, Major","enrollment":545},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT05550532","phase":"PHASE3","title":"A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":444},{"nctId":"NCT06993662","phase":"PHASE1","title":"The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rakitzi, Stavroula","startDate":"2025-06-02","conditions":"Anxiety, Depression, Obsessive-compulsive Disorder","enrollment":107},{"nctId":"NCT07393919","phase":"PHASE4","title":"Discontination of Antidepressants in Remitted Depression","status":"NOT_YET_RECRUITING","sponsor":"Universita di Verona","startDate":"2026-02-01","conditions":"Depression - Major Depressive Disorder","enrollment":150},{"nctId":"NCT06805851","phase":"","title":"Impact of Depression on Thermoregulation","status":"RECRUITING","sponsor":"Penn State University","startDate":"2025-03-01","conditions":"Depression, Selective Serotonin Reuptake Inhibitor","enrollment":64},{"nctId":"NCT06633016","phase":"PHASE2","title":"Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)","status":"RECRUITING","sponsor":"Autobahn Therapeutics, Inc.","startDate":"2024-09-20","conditions":"Major Depressive Disorder","enrollment":230},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT05455684","phase":"PHASE3","title":"A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-22","conditions":"Depressive Disorder, Major, Anhedonia","enrollment":513},{"nctId":"NCT03513185","phase":"","title":"Assessment of SSD in Outpatients Using SSS-CN","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-09-01","conditions":"Somatization Disorder","enrollment":1863},{"nctId":"NCT04829318","phase":"PHASE4","title":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2021-04-26","conditions":"Depressive Disorder, Major","enrollment":183},{"nctId":"NCT06443242","phase":"NA","title":"Efficacy and Safety of Low-dose Laser Acupuncture on Treating Insomnia Associated With Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Mohammad Farris Iman Leong Bin Abdullah","startDate":"2025-12-01","conditions":"Major Depressive Disorder, Insomnia","enrollment":120},{"nctId":"NCT07161492","phase":"NA","title":"A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2025-09","conditions":"Depressive Disorder, Major, Cognitive Impairment","enrollment":182},{"nctId":"NCT07153406","phase":"PHASE3","title":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2025-09-15","conditions":"Depressive Disorder","enrollment":220},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT05895747","phase":"PHASE2","title":"5-HTP and Creatine for Depression R33 Phase","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-09-28","conditions":"Major Depressive Disorder","enrollment":106},{"nctId":"NCT05976347","phase":"PHASE4","title":"Identifying and Treating Depression in the Orthopaedic Trauma Population","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-06-25","conditions":"Depression","enrollment":100},{"nctId":"NCT05830279","phase":"","title":"Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-05-01","conditions":"Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive, Cancer Pain","enrollment":600},{"nctId":"NCT04597190","phase":"PHASE4","title":"Sequenced Treatment Effectiveness for Posttraumatic Stress","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-06-01","conditions":"PTSD","enrollment":700},{"nctId":"NCT04338321","phase":"PHASE3","title":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2020-08-21","conditions":"Depressive Disorder, Major","enrollment":676},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT05109195","phase":"","title":"A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-26","conditions":"Depressive Disorder, Major","enrollment":7},{"nctId":"NCT05518149","phase":"PHASE3","title":"A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-22","conditions":"Depressive Disorder, Major","enrollment":840},{"nctId":"NCT05641623","phase":"PHASE2","title":"OSU6162 as add-on in SSRI/SNRI-resistant Depression","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2022-04-21","conditions":"Depression, Depressive Disorder, Treatment-Resistant, Depressive Disorder","enrollment":180},{"nctId":"NCT05650788","phase":"NA","title":"Exploration of Differences in Metabolite Concentrations by NMR Spectroscopy in the Ventral Striatum, Anterior Cingulate Cortex and Prefrontal Cortex in Euthymic Patients With Unipolar and Bipolar Type II Mood Disorders, as Well as in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2020-06-05","conditions":"Bipolar Disorder Type II, Mood Depressive Disorder","enrollment":60},{"nctId":"NCT04245748","phase":"PHASE4","title":"Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2020-03-01","conditions":"Anxious Depression, Depression","enrollment":84},{"nctId":"NCT04395183","phase":"PHASE2","title":"5-HTP and Creatine for Depression","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-03-01","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT02458690","phase":"PHASE2","title":"eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-07","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":216},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT05933538","phase":"PHASE4","title":"Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2024-08","conditions":"Depressive Disorder, Major","enrollment":110},{"nctId":"NCT05930912","phase":"","title":"Psychiatric Orders in Psychoanalytic Treatment of ASD","status":"UNKNOWN","sponsor":"Yang I. Pachankis, PhD","startDate":"2023-06-01","conditions":"PTSD, Autism Spectrum Disorder High-Functioning, OCD","enrollment":1},{"nctId":"NCT04355650","phase":"NA","title":"Augmented Human Intelligence in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-01-27","conditions":"Depression, Major Depressive Disorder","enrollment":126},{"nctId":"NCT04039022","phase":"PHASE3","title":"Open-Label Safety Study of AXS-05 in Subjects With Depression","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-07-08","conditions":"Major Depressive Disorder, Treatment Resistant Depression, Depression","enrollment":876},{"nctId":"NCT04019704","phase":"PHASE3","title":"A Trial of AXS-05 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-06-20","conditions":"Depression, Major Depressive Disorder","enrollment":327},{"nctId":"NCT02972398","phase":"NA","title":"N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2015-09","conditions":"Major Depressive Disorders","enrollment":200},{"nctId":"NCT04592159","phase":"PHASE2, PHASE3","title":"Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2021-02-01","conditions":"Post-Traumatic Stress Disorder","enrollment":""},{"nctId":"NCT02922725","phase":"PHASE4","title":"Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females","status":"TERMINATED","sponsor":"Brent Michael Kious, MD, PhD","startDate":"2016-11","conditions":"Major Depressive Disorder","enrollment":32},{"nctId":"NCT01503489","phase":"","title":"Risk Factors for AD-Associated Switch to Mania","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2005-10","conditions":"Bipolar Disorder","enrollment":221},{"nctId":"NCT04562324","phase":"NA","title":"Efficacy of Electroencephalography (EEG) Neurofeedback (NF) for the Treatment of Anxiety Disorder","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2019-09-10","conditions":"Anxiety Disorder, Healthy","enrollment":60},{"nctId":"NCT04497493","phase":"NA","title":"Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2020-05-22","conditions":"Major Depressive Disorders","enrollment":75},{"nctId":"NCT03249311","phase":"PHASE4","title":"Levomilnacipran in Healthy Males","status":"UNKNOWN","sponsor":"University of Ottawa","startDate":"2018-03-02","conditions":"None (i.e. Healthy Volunteers)","enrollment":36},{"nctId":"NCT04928937","phase":"","title":"Pharmacokinetics of SSRI/SNRI After Bariatric Surgery","status":"COMPLETED","sponsor":"Luzerner Kantonsspital","startDate":"2017-02-01","conditions":"Obesity, Depression","enrollment":63},{"nctId":"NCT04730934","phase":"","title":"Effects of the COVID-19 Pandemic on Fibromyalgia Patients","status":"COMPLETED","sponsor":"Kars State Hospital","startDate":"2021-01-01","conditions":"Fibromyalgia, Chronic Low-back Pain","enrollment":1360},{"nctId":"NCT03464383","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Treatment Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-07","conditions":"Anxiety, Depression, Epilepsy","enrollment":69},{"nctId":"NCT03491696","phase":"PHASE4","title":"Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.","status":"UNKNOWN","sponsor":"Centre Hospitalier Rouffach","startDate":"2018-12-22","conditions":"Depressive Disorder, Hormone Disturbance","enrollment":14},{"nctId":"NCT04528628","phase":"NA","title":"Optimization of Diagnosis and Treatment of Depression Based on Multidimensional Clinical Assessment Classification","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-10","conditions":"Major Depressive Disorder","enrollment":960},{"nctId":"NCT04509882","phase":"PHASE2","title":"Bear Bile Pill as add-on the Treatment of MDD","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-10-30","conditions":"Major Depressive Disorder","enrollment":120},{"nctId":"NCT03835715","phase":"PHASE4","title":"Study With Vortioxetine on Emotional Functioning in Patients With Depression","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2019-02-05","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT01204918","phase":"PHASE2","title":"Efficacy and Tolerability of Riluzole in Treatment Resistant Depression","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-06","conditions":"Depression","enrollment":104},{"nctId":"NCT02109939","phase":"NA","title":"Genomics Used to Improve DEpression Decisions","status":"COMPLETED","sponsor":"Assurex Health Inc.","startDate":"2014-04","conditions":"Major Depressive Disorder (MDD)","enrollment":1398},{"nctId":"NCT04209166","phase":"NA","title":"A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2019-08-12","conditions":"Major Depressive Disorder","enrollment":780},{"nctId":"NCT01811147","phase":"PHASE4","title":"Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2011-11","conditions":"Bipolar Disorder, Major Depression","enrollment":192},{"nctId":"NCT03018340","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2016-12","conditions":"Adjunctive Treatment of Major Depressive Disorder","enrollment":207},{"nctId":"NCT03522987","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Pilot Treatment Study","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05","conditions":"Anxiety, Depression, Epilepsy","enrollment":""},{"nctId":"NCT03973567","phase":"NA","title":"MRI Study of Antidepressants in the Treatment of Refractory Functional Dyspepsia","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-01-01","conditions":"Therapeutic Mechanism of Antidepressants for Refractory FD","enrollment":90},{"nctId":"NCT03432221","phase":"","title":"Switching From SSRI to Desvenlafaxine on Cognitive Functioning","status":"UNKNOWN","sponsor":"Corporacion Parc Tauli","startDate":"2018-04-03","conditions":"Major Depressive Disorder","enrollment":36},{"nctId":"NCT01421342","phase":"PHASE3","title":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":1522},{"nctId":"NCT03219008","phase":"PHASE4","title":"Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-08-01","conditions":"Depressive Disorder","enrollment":800},{"nctId":"NCT00049972","phase":"PHASE4","title":"Major Depressive Disorder Study In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-09","conditions":"Major Depressive Disorder","enrollment":646},{"nctId":"NCT00347269","phase":"PHASE4","title":"Primary Care Intervention Strategy for Anxiety Disorders","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-06","conditions":"Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder","enrollment":1004},{"nctId":"NCT01856127","phase":"PHASE4","title":"Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2013-01","conditions":"Sexual Dysfunction, Major Depressive Disorder","enrollment":4},{"nctId":"NCT01040208","phase":"PHASE3","title":"12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress","status":"TERMINATED","sponsor":"Sprout Pharmaceuticals, Inc","startDate":"2010-01","conditions":"Sexual Dysfunctions, Psychological, Depression","enrollment":111},{"nctId":"NCT01942785","phase":"PHASE3","title":"Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Major Depressive Disorder, Irritability","enrollment":55},{"nctId":"NCT02320240","phase":"","title":"Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2013-06","conditions":"Depression, Acute Kidney Injury","enrollment":3255526},{"nctId":"NCT01318434","phase":"PHASE2, PHASE3","title":"A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)","status":"COMPLETED","sponsor":"Euthymics BioScience, Inc.","startDate":"2011-02","conditions":"Major Depressive Disorder","enrollment":342},{"nctId":"NCT01796132","phase":"PHASE4","title":"Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-08","conditions":"Depressive Disorder, Lactation","enrollment":500},{"nctId":"NCT00395213","phase":"","title":"Antidepressant Safety in Kids Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-05","conditions":"Anxiety Disorders, Depressive Disorders, Eating Disorders","enrollment":569},{"nctId":"NCT02015546","phase":"PHASE3","title":"Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-12","conditions":"Major Depressive Disorder (MDD)","enrollment":70},{"nctId":"NCT00591565","phase":"NA","title":"An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2006-06","conditions":"Anxiety","enrollment":13},{"nctId":"NCT00411398","phase":"PHASE3","title":"A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2006-12","conditions":"General Anxiety Disorder, Social Anxiety Disorder","enrollment":15},{"nctId":"NCT00266409","phase":"PHASE4","title":"Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":"Generalized Anxiety Disorder, Panic Disorder","enrollment":418},{"nctId":"NCT01436643","phase":"PHASE4","title":"Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Depression, Relapsing-remitting Multiple Sclerosis","enrollment":54},{"nctId":"NCT01906268","phase":"NA","title":"Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-07","conditions":"Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder","enrollment":60},{"nctId":"NCT01152554","phase":"PHASE3","title":"A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Major Depressive Disorder, MDD, Depression","enrollment":813},{"nctId":"NCT01153347","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Major Depressive Disorder, Depression","enrollment":2409},{"nctId":"NCT01157078","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Major Depressive Disorder, Depression","enrollment":319},{"nctId":"NCT01197508","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Major Depressive Disorder","enrollment":696},{"nctId":"NCT01180400","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Major Depressive Disorder, Depression","enrollment":295},{"nctId":"NCT01601912","phase":"","title":"Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2013-02","conditions":"Whiplash Injuries","enrollment":59},{"nctId":"NCT01001559","phase":"","title":"Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis","status":"COMPLETED","sponsor":"Pamlab, Inc.","startDate":"2009-08","conditions":"Major Depressive Disorder","enrollment":242},{"nctId":"NCT01189825","phase":"NA","title":"Efficacy of Exercise for Sexual Side Effects of Antidepressants","status":"COMPLETED","sponsor":"University of Texas at Austin","startDate":"2009-06","conditions":"Sexual Dysfunction","enrollment":48},{"nctId":"NCT00944996","phase":"NA","title":"Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression","status":"COMPLETED","sponsor":"Tirat Carmel Mental Health Center","startDate":"2009-06","conditions":"Major Depression","enrollment":100},{"nctId":"NCT00437385","phase":"PHASE1","title":"Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2005-03","conditions":"Depression, Major Depression","enrollment":90},{"nctId":"NCT00246233","phase":"PHASE3","title":"CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2005-06","conditions":"Depressive Disorder, Major","enrollment":145},{"nctId":"NCT00534599","phase":"PHASE3","title":"Generalized Anxiety Disorder Adjunct Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-08","conditions":"Anxiety, Anxiety Disorders, Anxiety Neuroses","enrollment":409},{"nctId":"NCT01221935","phase":"","title":"Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Major Depressive Disorder","enrollment":2701},{"nctId":"NCT00993876","phase":"NA","title":"Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment","status":"COMPLETED","sponsor":"Zentrum für Integrative Psychiatrie","startDate":"2005-08","conditions":"Cognitive Performance in Major Depression","enrollment":45},{"nctId":"NCT00745017","phase":"PHASE1","title":"Stress Generation and Recurrent Depression: The Role of Differential Treatment Response","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2001-07","conditions":"Depression, Major Depressive Disorder","enrollment":72},{"nctId":"NCT00744406","phase":"PHASE2","title":"Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2003-07","conditions":"Depression, Major Depressive Disorder","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":250,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["citalopram","duloxetine","escitalopram","fluoxetine","fluvoxamine"],"phase":"marketed","status":"active","brandName":"SSRI/SNRI","genericName":"SSRI/SNRI","companyName":"UCB Pharma","companyId":"ucb-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SSRIs and SNRIs increase serotonin (and norepinephrine for SNRIs) in the brain by blocking their reuptake from the synaptic cleft, thereby enhancing mood regulation and emotional processing. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}